Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy CEL-SCI stock

Learn how to easily invest in CEL-SCI stock.

CEL-SCI Corp is a biotechnology business based in the US. CEL-SCI shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.

How to buy shares in CEL-SCI

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CVM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

CEL-SCI stock price (NYSE MKT: CVM)

Use our graph to track the performance of CVM stocks over time.

CEL-SCI shares at a glance

Information last updated 2022-07-02.
Latest market close$4.17
52-week range$2.49 - $12.90
50-day moving average $3.45
200-day moving average $6.69
Wall St. target price$15.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.87

Buy CEL-SCI shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CEL-SCI stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CEL-SCI price performance over time

Historical closes compared with the close of $4.17 from 2022-07-05

1 week (2022-06-30) -7.33%
1 month (2022-06-03) N/A
3 months (2022-04-07) 11.80%
6 months (2022-01-06) -38.95%
1 year (2021-07-07) -51.96%
2 years (2020-07-07) -69.74%
3 years (2019-07-05) 8.42
5 years (2017-07-06) 75.95%

CEL-SCI financials

Revenue TTM $28,558
Gross profit TTM $-23,108,897
Return on assets TTM -41.46%
Return on equity TTM -96.97%
Profit margin 0%
Book value $1.04
Market capitalisation $177.6 million

TTM: trailing 12 months

CEL-SCI share dividends

We're not expecting CEL-SCI to pay a dividend over the next 12 months.

Have CEL-SCI's shares ever split?

CEL-SCI's shares were split on a 1:25 basis on 14 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI shares which in turn could have impacted CEL-SCI's share price.

CEL-SCI share price volatility

Over the last 12 months, CEL-SCI's shares have ranged in value from as little as $2.49 up to $12.9. A popular way to gauge a stock's volatility is its "beta".

CVM.US volatility(beta: 2.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI's is 2.1561. This would suggest that CEL-SCI's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CEL-SCI overview

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. .

Frequently asked questions

What percentage of CEL-SCI is owned by insiders or institutions?
Currently 3.887% of CEL-SCI shares are held by insiders and 32.013% by institutions.
When does the fiscal year end for CEL-SCI?
CEL-SCI's fiscal year ends in September.
Where is CEL-SCI based?
CEL-SCI's address is: 8229 Boone Boulevard, Vienna, VA, United States, 22182
What is CEL-SCI's ISIN number?
CEL-SCI's international securities identification number is: US1508376076
What is CEL-SCI's CUSIP number?
CEL-SCI's Committee on Uniform Securities Identification Procedures number is: 150837409

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site